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Abstract 
 
BACKGROUND  
Middle income countries are facing an epidemic of non-communicable diseases, especially 
coronary heart disease (CHD). We used a validated CHD mortality model (IMPACT) to explain 
recent trends in Tunisia, Syria, the occupied Palestinian territory (oPt) and Turkey. 
METHODS 
Data on populations, mortality, patient numbers, treatments and risk factor trends from 
national and local surveys in each country were collated over two time points (1995-97; 2006-
09); integrated and analysed using the IMPACT model.  
RESULTS 
Risk factor trends: Smoking prevalence was high in men, persisting in Syria but decreasing in 
Tunisia, oPt and Turkey. BMI rose by 1-2kg/m2 and diabetes prevalence increased by 40%-50%. 
Mean systolic blood pressure and cholesterol levels increased in Tunisia and Syria. 
Mortality trends:  Age-standardised CHD mortality rates rose by 20% in Tunisia and 62% in 
Syria.  Much of this increase (79% and 72% respectively) was attributed to adverse trends in 
major risk factors, occurring despite some improvements in treatment uptake.  
CHD mortality rates fell by 17% in oPt and by 25% in Turkey, with risk factor changes 
accounting for around 46% and 30% of this reduction respectively. Increased uptake of 
community treatments (drug treatments for chronic angina, heart failure, hypertension and 
secondary prevention after a cardiac event) accounted for most of the remainder.  
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DISCUSSION 
CHD death rates are rising in Tunisia and Syria, whilst oPt and Turkey demonstrate clear falls, 
reflecting improvements in major risk factors with contributions from medical treatments. 
However, smoking prevalence remains very high in men; obesity and diabetes levels are rising 
dramatically.  
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Introduction 
 
Coronary heart disease (CHD) is the most common cause of mortality globally, generating more 
than 7 million deaths each year.  CHD is expected to remain a leading cause of death beyond 
20301 2. Different regions are at varying stages in their CHD epidemics. For example, after 
peaking in the 1960s, CHD mortality in Western countries has subsequently halved. Central 
European countries have experienced more recent and abrupt declines following 
socioeconomic transformations in 1989/19903. The drivers of these CHD mortality trends are 
increasingly well characterised in affluent countries.  Diverse studies generally suggested that 
risk factor improvements explain half to two thirds of the mortality declines with the remaining 
one third to half coming from evidence based treatments4-6. CHD and other non-
communicable diseases (NCDs) are increasing as a proportion of total mortality in most middle 
and low income countries1 2 7.  However, much less information on the CHD burden (mortality, 
morbidity and costs) and CHD trends are available from these populations. This is particularly 
worrisome for countries in the Eastern Mediterranean Region, where predictions suggest 
substantial increases in the number of NCD deaths by 20208. For countries in this region, there 
is therefore an urgent need to analyse local and regional CHD trends and quantify the impact of 
risk factors and treatments.  
 
Risk factor trends across the WHO-EMRO region were recently summarised in GBD Lancet 
papers9-12.   However, such analyses risk portraying a relatively “homogenous” view of the 
region, whereas mortality trends are strikingly heterogeneous. For instance, our analyses show 
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that CHD mortality is rising rapidly in many countries including Tunisia and Syria, but decreasing 
in other Mediterranean countries such as the occupied Palestinian territories and Turkey.   
It is clearly important to identify trends in CHD mortality in low and middle income settings and 
appraise their variations between countries, so as to inform effective policies to reduce the 
future disease burden.  Our aim was therefore to analyse recent CHD trends in Tunisia, Syria, 
occupied Palestinian territories (oPT, West Bank), and Turkey (middle income countries in the 
Eastern Mediterranean region), and assess the recent contribution of risk factor changes and 
evidence based treatments. These four countries were selected on the basis of a) data 
availability and quality,  b) previous successful collaborations, some of which had resulted in 
substantial relevant data collection over time, and  c)  representing a range of economic 
development, population size, and absolute mortality rates across this region (see Tables 1 and 
2).    
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Methods 
The socio-demographic and economic characteristics of the Tunisian, Syrian, oPt (West Bank), 
and Turkish populations are compared in Table 1. 
The IMPACT Model 
We used an updated version of the IMPACT CHD mortality model (Appendix 1). This has been 
employed and validated in a variety of countries from North America through Europe to China4 
13. Data on risk factor levels and current uptake levels of evidence-based treatments were 
identified by extensive searches for published and unpublished data, and complemented where 
necessary with specifically designed surveys.  
Data sources used to populate the model are detailed in Appendix 2 and in previous work14. In 
brief, they include:  
a)  Population and CHD mortality data (from national statistical agencies).  
b) Patient numbers and uptake of specific medical and surgical treatments in nine CHD patient 
groups. 
c)  Population trends in major cardiovascular risk factors (smoking, total cholesterol, systolic 
blood pressure, body mass index, diabetes and physical inactivity).   
 
In order to estimate trends, these data items were acquired for two time points (referred to as 
the initial and final years respectively). These were the most recent year with data available 
(final), and one 10-15 years previously (initial); 1997-2009 for Tunisia, 1996-2006 for Syria, 1998-
2009 for oPt and 1995 – 2008 for Turkey). Data were stratified by 10-year age groups and sex. Due 
to variations in data availability, there were some minor differences in the age groups included for 
each population (25+ in Tunisia and Syria; 25-74 in West Bank, oPt; 35-84 in Turkey).   
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Change in CHD deaths between the initial and final years 
The number of CHD deaths expected in the final year was calculated by applying the age and sex 
specific death rates in the initial year to the population age and sex structure in the final year. 
The observed CHD deaths in the final year were then subtracted to estimate the difference 
between the initial and final years. This was described as the number of deaths prevented or 
postponed (DPPs) if negative, or increased mortality if positive (the number the model attempts 
to explain in each country).  
 
Data on patient numbers and treatment uptakes during the initial and final years were 
obtained for nine mutually exclusive CHD subgroups: patients hospitalized during that year for 
an acute myocardial infarction (AMI) or unstable angina pectoris (UAP) or heart failure due to 
CHD, community-dwelling patients who were post-AMI survivors, patients with chronic angina, 
patients receiving  revascularisation (CABG or PCI), patients in the community with heart failure 
due to CHD (i.e. those treated outside of hospital), and individuals eligible for primary 
prevention being hypertensive (eligible for blood pressure lowering treatments) or having 
hypercholesterolaemia (eligible for lipid lowering therapy).  These data, along with information 
on uptake levels of evidence based treatments were obtained from a combination of national 
statistics, local surveys, grey literature, hospital records and specifically designed surveys as 
appropriate (Appendix 2). These were used for estimating treatment coverage in the initial and 
final years.  
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Data on trends in population risk factors (smoking prevalence, total cholesterol, systolic blood 
pressure, body mass index, diabetes) were obtained mainly from national and local surveys 
complemented by published and grey literature (Appendix 2). 
 
The mortality changes attributed to risk factor trends 
The deaths attributable to population changes in risk factor levels were estimated using one of 
two approaches. 
 
The regression  coefficient approach was used to quantify the population mortality 
impact of change in continuous risk factors (systolic blood pressure, total cholesterol and BMI). 
The mortality change was then estimated as the product of the CHD deaths observed in the initial 
year, the subsequent change in the risk factor, and the  regression coefficient quantifying the 
change in CHD mortality expected per unit of absolute change in the risk factor (Appendix 1). 
These regression coefficients were derived from international studies after controlling for all 
other coefficients included in the model (see Appendix 1, eTable3). For example, the coefficient 
for BMI is independent of that for BP, cholesterol and Diabetes. They also control for the effects 
of increased treatment uptake (for lowering blood pressure and cholesterol levels) over time 
(see Appendix 1, page 7).   
 
A second approach, population attributable risk fraction, was used for categorical 
variables- smoking, diabetes, and physical inactivity by applying Levin’s formula (Appendix 1). 
Lag times between the change in cardiovascular risk factor levels and change in CHD mortality 
rates were assumed to be relatively rapid15-18 and were therefore not specifically modelled.  
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CHD deaths are caused by multiple risk factors acting simultaneously. Enumerating mortality 
changes from risk factor trends should ideally therefore not use a simple additive approach. 
Instead, the effects of risk factor changes were jointly estimated using the cumulative risk-
reduction approach (a multiplicative approach). This can be stated in the equation: 
 
𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑒𝑓𝑓𝑒𝑐𝑡 = 1 − ((1 − 𝑎) ∗ (1 − 𝑏) ∗ (1 − 𝑐) ∗ … (1 − 𝑛)) 
Where n is the total number of additional risk factors (in this case 5 as in total we modelled 6)  
 
This cumulative effect of change in all risk factors over the study period was calculated by age 
and sex for each country (see Appendix 1, page 8-10). The ratio of the cumulative effect to the 
corresponding additive effect was then calculated, yielding 70 adjustment factors. These 
adjustment factors were used to scale down the additive DPPs for each risk factor. These 
adjusted DPPs, summed over all seven risk factors, then equalled the estimated total combined 
DPPs, capturing the multiplicative net impact of positive and adverse changes in risk factors. All 
risk factor DPPs quoted in the results tables refer to the adjusted DPPs. 
 
Estimating the mortality reduction attributable to medical and surgical treatments 
 
The model included all medical and surgical treatments for the nine mutually exclusive patient 
groups in both the initial and final years.  
 
Case-fatality data were obtained from large, unselected, population-based patient cohorts. 
Survival benefit over a one-year time interval was used for all treatments, as we are only 
interested in quantifying deaths prevented or postponed for at least one year. (Appendix 1) 
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The mortality reduction for each treatment was then calculated as the number of patients in 
each group, multiplied by the group age-sex-specific case fatality, the treatment uptake and the 
relative mortality reduction (efficacy). The efficacy of each therapeutic intervention was based 
on recent meta-analyses and randomised controlled trials.  (Appendix 1, eTable 1 ) 
 
The potential effect of multiple treatments in an individual patient was calculated conventionally 
using the Mant and Hicks cumulative relative benefit approach3.   
 
Treatment adherence and overlaps (Appendix 1, page 7)  
To avoid double counting, potential overlaps between different groups of patients were 
identified and adjusted. Adherence (the proportion of treated patients actually taking 
therapeutically effective levels of medication) was assumed to be 100% in hospital patients, 70% 
in symptomatic community patients, and 50% in asymptomatic community patients19-21. 
 
Sensitivity Analyses (Appendix 1, page 7) 
Similar to economic evaluation studies in health22, 95% uncertainty intervals around the model 
output (i.e., DPPs) were calculated using Monte Carlo simulation. This calculation involved 
replacing all fixed input parameters used in the model by appropriate probability distributions, 
and repeatedly recalculating the model output with values sampled from the defined input 
distributions (see Appendix 1 Page 10 eTable 1). We used the EXCEL add-in Ersatz software 
(www.epigear.com) to perform 10,000 runs to determine the 95% uncertainty intervals of the 
DPPs (2.5th and 97.5th percentile values corresponding to the lower and upper limits). For 
clarity, the “best” estimates only are reported in the text and the “maximum” and “minimums” 
in Tables 3 and 4.  
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Model validation: comparison with observed mortality falls 
The model estimates for the total number of deaths prevented or increased by each risk factor 
change and each treatment were summed.  These estimates were then compared with the 
observed changes in mortality in each age group for men and women.     
13 
Results 
Mortality trends 
Age adjusted CHD mortality rates rose by 20% in Tunisia and by 62% in Syria during the 
observation period for each country. In contrast, age adjusted CHD mortality rates fell by 17% 
in oPt and by 29% in Turkey (Table 2, Figure 1).   
These mortality trends resulted in approximately 680 additional deaths in Tunisia and some 
6,370 additional deaths in Syria, in the final year compared with the initial year. The declines in 
mortality rates resulted in approximately 120 fewer deaths in oPt and 35,720 fewer deaths in 
Turkey (see Table 2; minimum and maximum estimates are detailed in Tables 3 and 4). 
Large variations in CHD mortality trends were seen for men and women, with the relative 
changes generally favouring men, except in Tunisia (Table 2, Figures 2-3).   
Risk factor trends and associated mortality changes (Figure 2 and Table 3) 
SMOKING: Smoking prevalence decreased in all countries apart from Syria. Major changes were 
seen in Turkey; a fall of -11% (41% relative reduction) followed by oPt -10% (31% relative 
reduction). However smoking generally remained common among men (45% to 59% prevalence 
across the four countries). In Tunisian women, smoking prevalence doubled from 2% to 4%, 
resulting in some 30 additional deaths in the final model year. In Syria, smoking increased in 
women from 10% to 15% generating approximately 100 additional deaths in the final year. In oPt 
smoking prevalence decreased by 14% among men and by 7% in women. In Turkey, there was a 
major reduction in smoking prevalence of 20% in men and 2% in women, accounting for over 
7200 fewer CHD deaths in men and nearly 1200 fewer deaths in women (Table 3 and Appendix 
3).   
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SYSTOLIC BLOOD PRESSURE: Population mean systolic blood pressure (SBP) levels increased 
slightly in Tunisia (+0.6 mmHg) and rose substantially in Syria (+8.7 mmHg) but were broadly 
static in oPt and decreased in Turkey (-2.6 mmHg). 
Important differences were seen between men and women. In Tunisia, SBP increased on average by 4 
mmHg for men (129 mmHg to 133 mmHg), whereas in women it fell by 2 mmHg (131 mmHg to 129 
mmHg) – see Figures and Appendix 3. Similarly in oPt, average SBP decreased by 0.7 mmHg in men 
while among women it increased by 0.7 mmHg.  
The increase in SBP in Tunisia and Syria resulted in over 2,200 additional deaths according to our 
model estimates. The decrease in Turkey and oPt resulted in nearly 9,000 CHD fewer deaths in 
the two countries.   
CHOLESTEROL: Cholesterol levels increased in both Syria (+0.3 mmol/l) and Tunisia (+0.14 mmol/l). In 
Turkey levels remained broadly constant (+0.01 mmol/l), and in oPt decreased by 0.06 mmol/l.   
There were different trends for men and women. In Tunisia, cholesterol increased by 0.73mmol/l 
in men but decreased by 0.42mmol/l in women. In Syria, cholesterol levels increased in both men 
and women (0.22 and 0.38 mmol/l respectively), and rose modestly in Turkey (by 0.01 mmol/l in 
men and women). In oPt, cholesterol levels decreased in men (-0.07 mmol/l) and women (-
0.11mmol/l). Over 270 additional CHD deaths in Tunisia, 310 in Turkey and 1350 in Syria were 
attributable to the rises in cholesterol. The reduction in oPt resulted in approximately 40 fewer CHD 
deaths.  
BMI: BMI rose substantially in all four countries, increases ranging from 1.4 kg/m2 in Tunisia to 
3kg/m2 in oPt.  Absolute levels were much higher in women over the whole time period.  BMI 
generally rose more among men than women (except in Syria where the increase was similar in 
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men and women). More than 80 deaths in Tunisia, nearly 400 deaths in Syria, and over 3000 
deaths in Turkey were attributed to this obesity rise (Table 3).   
DIABETES: Diabetes prevalence also increased substantially in all four countries. Overall, a 43% 
relative increase was observed in Tunisia, 52% in Syria, 44% in oPt and 21% in Turkey. In general 
bigger increases were seen in men than in women. In Tunisia, diabetes prevalence increased 
more among men (12% to 19%) compared with women (12% to 16%). In Syria there was a similar 
relative increase in diabetes in men and women of +52%, but overall prevalence was higher in 
women (15% versus 11% in men). In oPt, the relative increases in diabetes were also around 2.5 
times as much in men (+64%) as in women (+26%), In Turkey diabetes  increased  similar in men  
and women (+21%). 
Our model estimated that over  5,000 additional CHD deaths could be attributed statistically to the 
rising diabetes prevalence in the region (approximately 30 in oPt, 60 in Tunisia, 600 in Syria, and around 
4,500 additional deaths in Turkey – Table 3).  
PHYSICAL INACTIVITY: Trends in physical inactivity are particularly difficult to interpret and could not 
be estimated at all in Syria. The contribution of physical inactivity trends was in general small because 
available data suggested that physical activity levels were low and remained low over the time period 
of the study.  
 
 
Effect of adjusting for cumulative risk factor trends 
 
Adjusting for multiple risk factor trends occurring simultaneously reduced the proportion of the 
total mortality change that could be explained by risk factors significantly. In absolute terms, 
this was reduced by between 6 percentage points in Turkey (from 36% to 30%); 10 in oPt (from 
16 
56% to 46%) to 18 in Syria (from 90% to 72%) and 19 percentage points in Tunisia (from 98% to 
79%) to and age group, compared with a simpler additive model.   
 
Estimating the contribution of medical and surgical treatments   
The impact of other primary preventive therapies (mainly statins) was low except in Tunisia 
(Table 4a, Figure 3). 
 
Overall contribution of evidence based treatments and risk factors 
Overall treatment uptakes increased in all countries. 
a) in countries with increasing mortality rates (Tables 3 & 4a) 
Adverse trends in risk factors explained approximately 79% of the observed mortality rise in 
Tunisia and over 72% of the increase in Syria, after adjusting for the effects of cumulative risk 
factor changes. In effect, this means that between 21% of the rise in Tunisia and 28% in Syrian 
cannot be explained. 
These mortality rises occurred in spite of improved treatment uptakes, resulting in 
approximately 450 fewer CHD deaths in Tunisia and some 2140 fewer deaths in Syria (Table 
4a).  
 
b) in countries with declining mortality rates (Tables  3 & 4b) 
In the occupied Palestinian territories (oPt) risk factor changes explained more than 46% of the 
overall mortality fall with treatments accounting for approximately 32% and in Turkey the 
relative contribution was approximately 30% for risk factor reduction and 47% for increased 
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treatment uptake (Table 3). This means that 22% of the decline was not explained in Turkey and 
23% in oPt.   
The largest medical contributions generally came from the community based treatments 
(treatment outside of hospital settings), particularly prescribing of aspirin and other secondary 
preventive medical therapies such as statins and anti-hypertensives after AMI, and community 
treatments for heart failure. In oPt and Turkey, hypertensive therapies also made important 
contributions.  
 
Model validation  
The IMPACT model has been replicated in over 15 countries worldwide, though most of these 
are high income countries. The model has also recently been validated for forward prediction in 
European populations23. The agreement for future projection was generally high (varying from 
90% of 106% of expected deaths prevented or postponed, albeit over short periods of time23 24. 
We assessed agreement between model estimates of the number of deaths prevented or 
postponed with official mortality statistics in these countries. The IMPACT Model estimates were 
apparently able to explain approximately 75% of the observed mortality changes in Turkey, and 
oPt, but less in Syria, and Tunisia respectively, although the fit depends on whether adjusted or 
unadjusted risk factor DPPs are combined, and whether risk factor and treatment trends are also 
summed (Tables 3 and 4, Appendix 4 Table 2). This may reflect that the model was originally 
developed for populations where CHD mortality is declining, or possibly reflect issues with data 
quality. However the model does not include trends in all CHD risk factors and hence 100% 
agreement would not be expected.     
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Discussion  
Summary of main findings 
CHD mortality rates have dramatically risen in Tunisia and Syria, but have thankfully fallen in 
the occupied Palestinian territory (oPt) and Turkey. These mortality trends mainly reflect 
changes in major cardiovascular risk factors, moderately alleviated by treatment contributions. 
These treatment contributions appeared slightly greater in Tunisia and Turkey; this may reflect 
a stronger primary health care system in the latter case25, and higher uptake of effective 
medical therapies for secondary prevention after AMI or CABG/PCI surgery. In Tunisia, uptake 
of initial treatments for AMI was also proportionately higher. Treatment contributions 
appeared weakest in Syria, probably reflecting a limited and deteriorating primary health care 
system (even before 2011)25, though there was some prescribing of effective drug treatments 
for chronic angina and heath failure. In all four countries, BMI and hence diabetes was rising, 
and these adverse trends would have resulted in increases in CHD mortality of about 2-10% 
and 10-20% respectively. However, trends in other risk factors were more heterogeneous. In 
Syria, smoking prevalence increased slightly (explaining 3% of the upward trend) but in Turkey 
and oPt smoking prevalence fell substantially (explaining almost 25% of the reduction in 
mortality). Systolic blood pressure also fell in Turkey (explaining almost another 25% of the 
downward trend), possibly reflecting both increased prescribing of anti-hypertensives and falls 
in salt consumption26 27. Cholesterol levels declined slightly in oPt and were relatively flat in 
Tukey, but around 40% of the small increase in CHD mortality in Tunisia could be attributed 
statistically to rising cholesterol levels, and just over 20% in Syria. Overall, in the two countries 
with increases in CHD mortality, (Tunisia and Syria), the adverse risk factor trends explained 
most (70-80% roughly) of the increase. In populations with falling CHD mortality rates, about 
one-third to half the decline was attributed to declines in major risk factors (smoking 
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cholesterol and  blood pressure), with another one-third to half attributed to increased uptake 
of effective medical and surgical treatments for CHD (see Appendix 4, Table 2). In some 
Western countries, the IMPACT model has been able to explain more of the mortality trends, 
but this may not be surprising given imperfect data. The data on risk factor changes generally 
came from high quality nationally representative studies using good valid measurement 
methods such as repeated BP measurements, fasting plasma glucose for diabetes, particularly 
in Tunisia.  However in Syria and oPt some data was based on sub-regional studies which we 
had to assume were nationally representative, particularly at the earlier time point. Risk factor 
data and quality are addressed in more detail in another publication14 and appendix 3. Routine 
data on treatment uptakes and trends was of more variable quality but we supplemented this 
by carrying out our own surveys and audits specifically for this project (see appendix 2). It is 
possible that our analyses may slightly over-estimate the treatment contributions, since 
hospitals that take part in such studies are more likely to be tertiary referral centres, and may 
hence be performing better than other secondary centres, although we adjust for this factor in 
probabilistic sensitivity analyses. We would also acknowledge that treatment data from the 
first time point (in the mid-1990s) were more uncertain and limited. However, this does not 
greatly influence model estimates since very little in the way of effective medical or surgical 
treatments were available in any of the 4 populations at the beginning of the model period.  
Death certification data is more variable in quality in low and middle income countries. 
Reassuringly, there has been no change in completeness of Tunisian death certification over 
this time period which could bias our results28, and death certification data from oPt was 
classed as “medium” quality according to WHO criteria29. In Turkey, analyses of causes of death 
from a previous national burden of disease study were used to adjust death certification 
estimates30. Whilst there are concerns about national death registry deaths in Syria, we used 
alternative sources (the Aleppo Household survey)31, which we considered more valid albeit at 
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the possible cost of generalisability.The diverging trends powerfully emphasise that regions 
should not be treated homogeneously32. Previous Global Burden of Disease analyses33 
projected specific risk factor trends against the levels and changes in wealth and urbanisation in 
around 100 developing countries. For example, with increasing affluence both obesity and 
cholesterol levels tend to increase.  Our study shows that CHD death rates are rising in Tunisia 
and even more substantially in Syria (prior to the current conflict), the poorest of the four 
countries (Gross National Income in International Dollars (Purchasing Power Parity) GNI I$ 4,010 
in 2005, and compared with Tunisia (GNI 6,820).  By contrast, Turkey, with a far higher GNI of 
11,330 demonstrated clear mortality falls. Furthermore, all four populations experienced 
substantial increases in BMI, with Syria showing the greatest increase, and Turkey the least.  
The occupied Palestinian territory (oPt) appears an interesting outlier, with slight cholesterol falls 
(and generally favourable risk factor trends) despite apparently very modest levels of wealth and 
the lowest GNI of the four (GNI I$2,710).  However, there are known difficulties in estimating GNI 
for the oPt34.  The mortality falls may reflect substantial international donations, high levels of 
education and literacy and a relatively well developed public health system35 36, partly facilitated 
by a small population size.  Furthermore, it suggests that CHD mortality trends cannot simply be 
predicted by levels of economic development.  
Perhaps most critical in explaining differences across the region are the smoking levels and 
trends. Smoking prevalence remained very high in men in Syria and Tunisia but declined in 
Turkey and oPt. Although smoking is relatively uncommon among women in Tunisia and Syria, 
both may be underreported (particularly as most national sources are self-reported) and there 
are also worrying signs that it may be increasing, particularly in younger people37.  
Different trends were seen for obesity between men and women. Although greater increases in 
BMI were observed in men, mean BMI remains much higher in women, particularly in Syria and 
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Tunisia. The high levels of female obesity presumably reflect traditional gender roles, gender 
inequality, and limited opportunities for women to leave the home environment (and partake 
in any physical activity). Data on physical activity are seriously limited across the region; 
however a recent Tunisian survey38 demonstrated very low levels of female participation in 
regular exercise of any kind. Trends in other risk factors were broadly similar by gender. 
Dietary trends 
Rapid risk factor and mortality changes observed in this study clearly reflect substantial 
economic and nutritional transitions in the Middle East. A dramatic rise in per capita energy 
and fat supplies in most countries has occurred over the past four decades. For example, 
between 1971 and 1997, calorie intakes rose by over 40% in Syria and Tunisia, (from 2,340 to 
3,350 calories in Syria and from 2,280 to 3,280 calories in Tunisia)39. Fat intakes similarly 
increased by over 60% over the same time period39. Sugar consumption may also have risen39-
41, whilst intakes of fruit, vegetables and fibre have all fallen39. The high calorie intakes, and 
limited physical activity have resulted in particularly high obesity rates, and hence escalating 
diabetes prevalence in this region.  Sodium intake is also high, thereby increasing blood 
pressure26. Rapidly increasing urbanisation probably underlies some of the dietary trends, with 
increased availability of processed foods, and possibly compounded by lower requirements for 
routine physical activity. In Turkey for example, between 1988 and 2008 the proportion of the 
population dwelling in urban areas increased from 25% to 75%.  
Methodological adjustment for cumulative risk factor trends 
The methodological refinement in this paper, accounting for multiple risk factor trends 
occurring simultaneously, significantly affected the proportion of the mortality trend that could 
be attributed to individual risk factor changes, reducing it by up to nearly 20% compared with 
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previous analyses. This contrasts with a previous study which did not demonstrate significant 
differences between these two approaches in a UK setting34. This difference may reflect the 
rapid risk factor trends that have been observed in the middle income countries in this study, 
and suggests that this refinement is most critical in countries in transition, undergoing rapid 
epidemiological changes. However, most current global modeling studies that attribute 
mortality trends to specific risk factor trends do not generally use a cumulative approach. Our 
study thus provides evidence of the importance of specific modeling approaches in this 
context, as well as original data for this under-researched region. 
Increasing uptake of evidence-based treatments 
Some favourable trends in the uptake of effective treatments have occurred, particularly in oPt 
and Turkey. The major contributors were improved uptake of aspirin and other secondary 
prevention medications, plus community heart failure treatments. Although the patterns were 
broadly similar there were some important differences between countries. For instance Tunisia 
had a much higher uptake of statins for primary prevention, but in other populations these 
uptakes remained low at the end of our period of analysis (approximately 2008), suggesting 
significantly greater potential with increasing use in the future42. Simple, accepted drug 
regimens or combinations (generally including aspirin, a calcium channel blocker, ACE inhibitor 
and statin) may be cost-effective for CHD patients even in low income settings and merit 
further study43 44.  However, treatment uptakes are still generally very low45 emphasising the 
remaining potential for cheap, effective medical therapies to help reduce CHD mortality rates.     
 
 
Strengths and limitations of the data and IMPACT model methodology 
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Modelling studies have a number of potential strengths, providing integration and simultaneous 
consideration of large amounts of data. The IMPACT Model has been widely used to explain CHD 
mortality trends, and has now been validated in over 15 high income populations34. However, 
this is the first analysis of middle income populations in the Middle East. 
We acknowledge many limitations. All models are dependent on the quality and extent of data 
available, and the outcome data (CHD mortality) is particularly important. Mortality trends by 
cause of death remain uncertain in many low and middle income countries due to incomplete 
or inaccurate coding, and a lack of trend data. Global Burden of disease analyses highlight the 
significant declines in adult mortality seen in many low and middle income countries in recent 
decades46. Life expectancy has risen in all 4 populations, but this is driven mainly by substantial 
declines in infant mortality47.  As CHD is a major component of total mortality, this might lead 
us to expect that age-specific CHD mortality is also falling globally. However, our data from 
Syria and Tunisia demonstrated increasing age-specific CHD mortality in recent years. In 
support of our findings, major CHD risk factors (smoking, blood pressure, and blood 
cholesterol) which together account for about 85% of variation in CHD mortality48 were either 
stagnant or increased in Syria and Tunisia over this time period; no substantial decreases were 
observed. Reassuringly, there has been no change in completeness of Tunisian death 
certification over this time period which could bias our results28, and whilst there are concerns 
about national death registry deaths in Syria, we used alternative sources (WHO and the 
Aleppo Household survey). A picture of continued adult mortality decline is by no means clear 
cut since other authors using the Demographic and Health surveys suggest that mortality 
decline has recently flattened in some MENA countries (Jordan, Yemen and Morrocco)49. 
Further, an increases in age-specific CHD mortality has also recently been reported in the 
largest country in this region (Egypt46). Hence our detailed analyses by country highlight the 
heterogeneity in cause of death trends among middle income countries. The Middle East 
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suffers particularly high male smoking rates and very low levels of physical activity; BMI and 
diabetes have been increasing faster than elsewhere in the world.  
Overall, the IMPACT model apparently explained up to 77% of the mortality trend observed in 
each country. This appears acceptable, particularly considering the variable death certification 
and imperfect risk factor measurement across the region. 
The model itself makes many simplifying assumptions. First it ignores potential lag times 
between changes in a risk factor and change in mortality, however, evidence suggests that lag 
times can be very short in practice15-18. It assumes a log-linear association between risk factors 
and CHD mortality; and the regression approach implicitly assumes that other, unmeasured risk 
factors have not changed over the model time period. This is not likely to be the case in 
practice. It assumes that trial estimates (efficacy) of medical and surgical treatments can be 
realised in practice; however, it does account for variable uptake and compliance of 
treatments. Estimates of one-year case-fatality had to be obtained from international rather 
than national sources and are thus uncertain (see eTable 3).  We did not explicitly consider 
competing risks. However, reductions in smoking prevalence (in Turkey and oPt) should also 
reduce death rates from common cancers and respiratory diseases. Increases in BMI and 
diabetes however might also increase risk of deaths from diabetes or cancers. The model does 
account for changes in age structure over time, which are small over this relatively short time 
period.  The data itself are only available at the population level.  The model itself is thus 
essentially ecological in nature. However, we only include treatments and risk factors where 
there is strong evidence of a causal relationship with CHD mortality.  
Naturally, data availability was variable across the countries involved. We populated the 
models with “national level” data or data from surveys covering a range of representative areas 
(such as in Turkey). Most of the major risk factors were measured rather than self-reported e.g. 
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BMI was measured as height and weight, SBP and total cholesterol and diabetes were also 
measured using appropriate blood pressure monitors and blood tests. Smoking status is usually 
self-reported in surveys. While generally considered valid, this could result in an underestimate 
of smoking status, particularly among women in countries like Tunisia, where female smoking is 
still culturally frowned upon50. Physical inactivity is also self-reported, and could be less 
reliable. Using national level or regional data may also conceal important heterogeneity within 
countries e.g. by urban / rural location or socio-economic status30 31 51-53.  It is possible that the 
relative contribution to CHD mortality trends from increased treatment uptake could be lower 
in some poorer, rural regions where health insurance coverage is lower and services weaker.  
For example, situational analyses of NCD clinics, a separate part of this EC funded project, 
found that both patient record keeping and staff skills were weaker in poorer rural areas, and 
along with inadequate referral arrangements, could potentially lead to poorer treatment 
outcomes25.  
Our model explains change in mortality over time, rather than the absolute levels.  Whilst 
trends within the four countries are considered reliable (Appendix 2), comparisons between 
them should be made cautiously, due to potential differences in coding practices and quality of 
death certification. The model probably captures all major contributions to mortality change, 
but the contributions of each component have substantial uncertainty.  However, probabilistic 
sensitivity analysis demonstrated that the relative contributions of risk factor changes and 
treatments to the overall mortality trends were reasonably consistent.  
The current model only reports on mortality. Other outcomes (incidence, life years gained or 
lost, and cost-effectiveness) though potentially valuable54 would require further data which is 
not readily available in the region.  However this merits attention in future work.   
Policy Implications 
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Our results may be cautiously generalisable to other low and middle income populations, 
especially in the Eastern Mediterranean region (recognising the many potential similarities in 
social, cultural and economic attributes of these societies). It also highlights both the 
challenges (missing data) and benefits (identifying potential heterogeneity and effects of 
individual treatments) of grounding analysis in country-specific data, compared with other 
approaches. Clearly, the political catastrophe that has engulfed Syria since 2011 inevitably 
reduces the immediate relevance of the lessons that may be drawn from our Syrian findings; 
however, in the longer term these may provide a baseline for subsequent policy analysis and 
future policy development in a post-conflict era.   
Our findings highlight the consistently powerful effects of even small changes in the major 
cardiovascular risk factors, smoking, blood pressure and cholesterol.  Furthermore, dramatic 
rises in diabetes have occurred across the region, mainly reflecting marked increases in BMI 
and adverse trends in diet (particularly salt, sugar, saturated fat and calorie intakes). These 
dietary and obesity trends also underlie most of the observed increases in blood pressure and 
cholesterol levels.   
  
These current adverse risk factor trends are very worrying and represent a clear wake-up call. 
They justify stronger regional and global policy responses targeting smoking, unhealthy diet, 
and physical inactivity.  Effective interventions exist55 56 57-59;  but their implementation may be 
politically challenging across diverse cultures. However, our analysis clearly demonstrates 
different trends across the countries, suggesting that national policies should perhaps be 
tailored to local priorities.  Countries such as oPt and Turkey have performed relatively well on 
reducing SBP, cholesterol and smoking (despite on-going political difficulties).  Neighbouring 
countries might therefore perhaps consider similar policies.  Mortality trends broadly reflect 
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changes in risk factors more than improved treatment uptake. In countries with well-
established primary health care systems, medications may provide a useful strategy in addition 
to population-based interventions. Yet, whilst appropriately targeted medical interventions can 
be cost-effective, they may be difficult to implement, especially in countries without 
comprehensive primary health care. Population based policy interventions to reduce risk 
factors can also be challenging to implement and enforce, and the evidence base for reducing 
obesity and diabetes in low and middle income countries is sparse.  However, evidence from 
other countries suggests that tobacco control and dietary policies can be powerful, rapid and 
cost saving.55 56 60, 61 62   These evidence-based policy interventions should therefore be strongly 
recommended for the prevention of both CHD and other non-communicable diseases.  
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Table 1:  
Socio-demographic and economic comparison of the four Eastern Mediterranean countries 
 
Country Population 
(millions) 
Life 
expectancy (at 
birth) 
% of total 
mortality 
attributed to 
CHD  
Per capita GNI 
PPP$ 
Tunisia 10.1 74 27.14% 6,820 
Syria 18.9 75 34.25% 4,010 
Palestine (oPt) 3.8 72 21.98% 2,710* 
Turkey 70 74 18.66% 11,330 
Footnotes: GNI per capita PPP$ is Gross National Income in PPP US $ 
Sources: Arab Human Development Report 2009. UNDP, HDR 2007/2008 for Tunisia, Syria and oPt (data for 2005). 
Turkey Statistical Institute for Turkish data (2007).  
Per capita GNI from World Bank Development Indicators (UN data, 2005).  
Life expectancy from World Bank 
http://www.indexmundi.com/facts/indicators/SP.DYN.LE00.IN/compare?country=sy. 
Proportion of all deaths from CHD http://vizhub.healthdata.org/gbd-compare/ (year 2010) 
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Table 2:Crude CHD mortality rates and trends in the four Eastern Mediterranean countries   
 
Country 
(years) 
Sex Population 
(,000) 
Number 
of deaths 
Rate/ 
105 
Number  
of deaths 
Rate/ 
105 
%  
change  
in  
rate 
% change in 
directly age-
standardised 
rate$ 
[annual change %] 
Observed 
increase 
or 
decrease 
in deaths* 
  Initial 
Year 
Final 
year 
Initial  year Final  year    
Tunisia Total 4301 5700 2106 49 3633 64 + 30 +20  
[+1.7 % 
p.a.] 
+682 
(1997-
2009) 
Men 2126 2789 1492 70 2429 87 + 24  +332 
Women 2176 2911 614 28 1205 41 + 47  +350 
          
Syria Total 5013 7410 5429 108 12503 169 + 56 +62 
[+6.2% 
p.a.] 
+6372 
(1996 -
2006) 
Men 2538 3735 3608 142 8119 217 + 53  +3772 
Women 2475 3675 1821 73 4384 119 + 62  +2660 
          
oPt 
(1998 -
2009) 
Total 610 913 520 85 586 64 -25 -17 
[-1.5% 
p.a.] 
-122 
Men 302 461 318 105 394 86 - 19  -60 
Women 308 452 202 66 192 43 - 35  -62 
           
Turkey 
(1995 – 
2008) 
Total 18932 27958 79066 418 96366 345 -17 -29 
[-2.2% 
p.a.] 
-35,718 
Men 9418 13655 42938 456 49910 366 -20  -17,162 
Women 9514 14303 36128 379  46457 324 -14  -18,556 
 
Footnotes: 
37 
$CHD mortality rates for ages 35-74 (this age range chosen to be consistently available from all 4 populations), standardised to the World Standard 
Population. 
*This figure represents the observed change in mortality using indirect standardisation i.e. after accounting for changes in the age-sex structure of the 
population over time. This is the change in deaths which the model then attempts to explain. It applies only to the final year of the period (2006 in Syria, 
2008 in Turkey, 2009 in oPt and Tunisia.  
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Table 3: Risk factor trends and consequent mortality changes in the four Eastern Mediterranean countries  (men & women combined) 
 Risk Factor 
Prevalence Absolute 
change in 
risk factor* 
Changes in deaths (increases or 
decreases)* 
% of total 
mortality 
trend 
Country  Initial year Final year  Estimated Min Max  
Tunisia 
(1997 – 2009) 
Smoking 23.9 22.7 -1.2 -14 -53         24 -2.1 
SBP (mmHg) 130.4 131.0 +0.60 +166 +20 +350 +24.3 
Cholesterol (mmol/l) 4.59 4.73 +0.14 +273 +204 +384 +40.0 
BMI (kg/m2) 26.0 27.5  +1.44 +86 +60 +112 +12.6 
Diabetes % 12.1 17.3 +5.2 +62 +4 +123 +9.2 
Physical inactivity% 98 85 -13 -35 -48 -23 -5.1 
 Total    +538 +368 +777 +78.9% 
         
Syria 
(1996 -2006) 
Smoking 33 37 +4 +171 -216 +549 +2.7 
SBP (Systolic BP) 122.2 130.9 +8.7 +2073 +1209 +3576 +32.5 
Cholesterol 5.05 5.34 +0.29 +1348 +1006 +1508 +21.2 
BMI 28.0 29.7 +1.8 +373 +266 +479 +5.9 
Diabetes  9 13 +4 +636 +242 +1013 +10.0 
Physical inactivity% - - - - - - - 
 Total    +4601 +3428 +6186 +72.2% 
         
oPt (West Bank) 
(1998 -2009) 
Smoking 32% 22% -10 -29 -78 +11 -23.7 
SBP (Systolic BP) 121.4 121.3 -0.10 -33 -235 155 -27.3 
Cholesterol 5.0 4.94 -0.06 -39 -140 46 -32.3 
BMI 28.0 31.0 +3 +2 -23 +28 +1.7 
Diabetes % 9 12 +3 +28 -16 +71 +22.7 
Physical inactivity% 84 92 +8 +16 +8 +17 +10 
 Total    -56 -160 +294 -45.7% 
         
Turkey 
(1995 – 2008) 
Smoking% 27 16 -11 -8423 -10205 -6679 -23.6 
SBP  127.2 124.6 -2.6 -8723 -12453 -4763 -24.4 
Cholesterol 4.96 4.97 +0.01 +310 -2238 +2797 +0.9 
BMI 27.4 29.0 +1.6 +3310 +2783 +3878 +9.3 
Diabetes % 15.5 18.7 +3.2 +4456 +2236 +6651 +12.5 
Physical inactivity% 70 65 -5 -1683 -2418 -1085 -4.7 
 Total    -10763 -16191 -4955 -30.1% 
*Footnote:  A positive value denotes an increase in the risk factor and an increase in deaths attributed to the risk factor increase. A negative value denotes a decrease in 
the risk factor and a consequent decrease in deaths attributed to the risk factor.  Physical activity data not available from Syria. Individual rows may not sum to their sub-
totals due to rounding.  
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Table 4a: Treatment contributions: numbers of patients in specific groups and CHD 
deaths prevented or postponed in Tunisia and Syria where CHD mortality was rising  
 (men and women combined) 
1.  
Country Treatment group Eligible 
Patients  
Deaths prevented 
or postponed 
(estimates) 
Estimated % 
reduction in CHD 
mortality attributed 
to treatments 
Best (Min) (Max) Best (Min) (Max) 
Tunisia Acute Myocardial Infarction (AMI) 4505 89 78 101 7.8 6.9 8.9 
Unstable Angina 6755 77 67 88 6.8 5.9 7.8 
Secondary Prev Post AMI 24058 95 87 103 8.4 7.7 9.1 
Secondary Prev Post CABG/PCI 1300 3 2 3 0.3 0.2 0.3 
Chronic Angina 53436 0 -19 15 0.0 -1.7 1.3 
Hospital Heart Failure 3614 37 22 55 3.3 2.0 4.9 
Community Heart Failure 25298 49 43 55 4.3 3.8 4.9 
Hypertension Treatment 1496744 80  38 138 7.1 3.4 12.2 
Statins primary prevention 601743 21 18 24 1.9 1.6 2.1 
 Total*  448 376 530 39.7 33.2 46.9 
         
Syria Acute Myocardial Infarction (AMI) 18002 287 250 321 3.4 2.9 3.8 
Unstable Angina 22877 150 142 158 1.8 1.7 1.9 
Secondary Prev Post AMI 78976 372 280 481 4.4 3.3 5.7 
Secondary Prev Post CABG/PCI 26316 65 46 84 0.8 0.5 1.0 
Chronic Angina 319974 803 638 1013 9.4 7.5 11.9 
Hospital Heart Failure 6927 84 -9 168 1.0 -0.1 2.0 
Community Heart Failure 52251 332 279 376 3.9 3.3 4.4 
Hypertension Treatment 863425 45 17 78 0.5 0.2 0.9 
Statins primary prevention 307295 6 4 10 0.1 0.0 0.1 
 Total*  2145 1648 3170 25.2 23.0 27.4 
 
Footnotes:  
The denominator is the estimated total number of CHD deaths in the absence of any treatments i.e. Tunisia 
1130 (680+450) and Syria 8515 (6370+2145).  
For Tunisia, chronic angina treatment in the community (best estimate) is zero since aspirin use was already 
high in the model base year (1997), and hence there was little scope for increase over time.  
*The totals row does not represent the sum of each treatment component due to the bootstrap methodology.  
 
KEY:  
AMI = Acute myocardial infarction 
CABG = Coronary artery bypass graft surgery 
PCI = Percutaneous intervention 
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Table 4b: Treatment contributions: numbers of patients in specific groups and CHD 
deaths prevented of postponed in the oPt and Turkey where CHD mortality was falling 
(men and women combined) 
 
Country Treatment group Eligible 
Patients  
Deaths prevented 
or postponed 
(estimates) 
% of the mortality 
change explained 
Best (Min) (Max) Best (Min) (Max) 
oPt Acute Myocardial Infarction (AMI) 489 2 2 2 1.9 1.3     1.7 
Unstable Angina 489 1 1 1 1.1 1.0 1.2 
Secondary Prev Post AMI 2266 8 6 10 7.3 5.0 8.6 
Secondary Prev Post CABG/PCI 1974 2 2 3 1.9 1.5 1.9 
Chronic Angina*** 22180 10 9 11 8.4 7.2 8.8 
Hospital Heart Failure 468 2 2 3 1.5 1.5 2.1 
Community Heart Failure 2342 7 5 8 5.3 4.5 6.2 
Hypertension Treatment 81894 5 4 6 4.1 3.1 6.2 
Statins primary prevention 7030 0 0 0 0 0 0.0 
 Total  38 29 46 31.5 23.4 37.7 
         
Turkey Acute Myocardial Infarction (AMI) 91317 1677 1448 1930 4.7 4.1 5.4 
Unstable Angina 45658 638 562 722 1.8 1.6 2.0 
Secondary Prev Post AMI 759071 4570 4100 5088 12.8 11.5 14.2 
Secondary Prev Post CABG/PCI 273379 1752 1401 2160 4.9 3.9 6.0 
Chronic Angina*** 103293 2622 2046 3265 7.3 5.7 9.1 
Hospital Heart Failure 46511 1025 891 1144 2.8 2.5 3.2 
Community Heart Failure 424511 2338 2074 2632 6.5 5.8 7.4 
Hypertension Treatment 10553133 2153 1899 2427 6.0 5.3 6.8 
Statins primary prevention 4483287 41 32 53 0.1 0.1 0.1 
Total  16794 16026 17598 47.0 44.9 49.3 
  
 
KEY:  
AMI = Acute myocardial infarction 
CABG = Coronary artery bypass graft surgery 
PCI = Percutaneous intervention 
 
 
 
 
 
